Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Ptc Therapeutics (PTCT)

Ptc Therapeutics (PTCT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,470,440
  • Shares Outstanding, K 65,480
  • Annual Sales, $ 306,980 K
  • Annual Income, $ -251,580 K
  • 60-Month Beta 1.40
  • Price/Sales 11.01
  • Price/Cash Flow N/A
  • Price/Book 6.14
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -4.50
  • Most Recent Earnings -1.81 on 04/30/20
  • Next Earnings Date 08/04/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -1.24
  • Number of Estimates 4
  • High Estimate -0.95
  • Low Estimate -1.52
  • Prior Year -0.66
  • Growth Rate Est. (year over year) -87.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
46.76 +13.34%
on 06/15/20
55.00 -3.64%
on 06/25/20
+2.05 (+4.02%)
since 06/02/20
3-Month
40.03 +32.40%
on 04/08/20
55.00 -3.64%
on 06/25/20
+8.04 (+17.88%)
since 04/02/20
52-Week
30.79 +72.12%
on 03/17/20
59.89 -11.50%
on 02/19/20
+8.08 (+17.99%)
since 07/02/19

Most Recent Stories

More News
PTC Therapeutics Announces CHMP Recommendation of Translarna™ (ataluren) Label Update for Non-Ambulatory Patients with Duchenne Muscular Dystrophy

, /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended by a majority...

PTCT : 53.00 (+2.71%)
Look for Shares of Ptc Therapeutics to Potentially Pullback after Yesterday's 2.78% Rise

Ptc Therapeutics (NASDAQ:PTCT) traded in a range yesterday that spanned from a low of $49.67 to a high of $52.54. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high...

PTCT : 53.00 (+2.71%)
PTC Therapeutics to Commence Phase II/III Coronavirus Study in US

PTC Therapeutics (PTCT) gets an FDA sanction to begin a phase II/III study on its DHODH inhibitor PTC299 as a potential treatment of COVID-19. The study will start in the United States shortly.

REGN : 622.45 (+2.18%)
LLY : 163.87 (+0.35%)
PTCT : 53.00 (+2.71%)
IMUX : 12.30 (+4.77%)
PTC Therapeutics Initiates Phase II/III Study for Coronavirus

PTC (PTCT) commences a phase II/III study to evaluate PTC299, a dihydroorotate dehydrogenase (DHODH) inhibitor, as a potential treatment for COVID-19.

AZN : 53.80 (+0.90%)
RHHBY : 43.7900 (-0.55%)
AMGN : 258.24 (+1.22%)
PTCT : 53.00 (+2.71%)
Edgewise Therapeutics Appoints Kirsten L. Gruis, M.D., M.S. as Chief Medical Officer

Edgewise Therapeutics, a biopharmaceutical company developing small molecule therapies for musculoskeletal diseases, today announced the appointment of Kirsten L. Gruis, M.D., M.S. to the newly created...

PTCT : 53.00 (+2.71%)
WVE : 9.91 (-9.83%)
PTC Therapeutics Announces the Initiation of a Phase 2/3 Clinical Trial to Evaluate PTC299 for the Treatment of COVID-19

, /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that the U.S. Food and Drug Administration has authorized the initiation of a Phase 2/3 trial to investigate PTC299, a dihydroorotate...

PTCT : 53.00 (+2.71%)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

, /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 10, 2020 it approved non-statutory stock options to purchase an aggregate of 54,675 shares of its common stock and...

PTCT : 53.00 (+2.71%)
PTC Therapeutics Announces 2-year Data from Part 1 of SUNFISH and New Data from JEWELFISH Trials for Risdiplam in Patients with Spinal Muscular Atrophy

, /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced two-year data from Part 1 of the SUNFISH trial in children and adults with type 2 or 3 spinal muscular atrophy (SMA) and new preliminary...

PTCT : 53.00 (+2.71%)
PTC Therapeutics Launches New "Talent Pipeline Program" to Help Students who Graduated During the 2020 COVID-19 Pandemic

, /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the Talent Pipeline Program (TPP), a one-year global internship program aimed at providing recent graduates real-world...

PTCT : 53.00 (+2.71%)
After Yesterday's Decline of 1.98%, Ptc Therapeutics Offers Investors Better Value

Ptc Therapeutics (NASDAQ:PTCT) traded in a range yesterday that spanned from a low of $48.41 to a high of $49.68. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of...

PTCT : 53.00 (+2.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade PTCT with:

Business Summary

PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States.

See More

Key Turning Points

2nd Resistance Point 54.75
1st Resistance Point 53.87
Last Price 53.00
1st Support Level 51.63
2nd Support Level 50.27

See More

52-Week High 59.89
Last Price 53.00
Fibonacci 61.8% 48.77
Fibonacci 50% 45.34
Fibonacci 38.2% 41.91
52-Week Low 30.79

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar